The sale was conducted under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for selling stocks to avoid potential conflicts of interest. This plan was adopted by McDonnell on March 8, 2024. InvestingPro subscribers can access 15+ additional insights about Agilent's valuation and performance metrics, including detailed analysis of insider trading patterns and comprehensive Pro Research Reports. InvestingPro subscribers can access 15+ additional insights about Agilent's valuation and performance metrics, including detailed analysis of insider trading patterns and comprehensive Pro Research Reports.
The sale was conducted under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for selling stocks to avoid potential conflicts of interest. This plan was adopted by McDonnell on March 8, 2024.
In other recent news, Waters Corp (NYSE:WAT). experienced a stock decline following the U.S. Commerce Department's announcement of new export controls on biotechnology equipment, citing national security concerns. These regulations could disrupt the sales and supply chains of affected companies, including Waters Corp. In response to these developments, the Chinese Embassy in Washington stated that China "firmly opposes any country's development, possession or use of biological weapons."
In the meantime, Agilent Technologies Inc (NYSE:A). has been the focus of several analyst notes. Stifel reiterated its Buy rating on Agilent's stock, highlighting the company's operating margin expansion and emphasis on PFAS testing as significant growth drivers. Similarly, Baird maintained its Outperform rating on Agilent's stock, noting the company's commitment to productivity and efficiency as key drivers for future performance. Bernstein SocGen Group also maintained its Market Perform rating for Agilent, following the company's Investor Day event.
Agilent reported a Q4 revenue of $1.701 billion for fiscal year 2024 and provided full-year fiscal 2025 revenue guidance of $6.79-$6.87 billion. The company's non-GAAP EPS is forecasted to be between $5.54 and $5.61. Agilent also secured Class C In Vitro Diagnostic Regulation (IVDR) certification for its PD-L1 IHC 28-8 pharmDx, a critical assay used in determining patient eligibility for specific cancer therapies. The company has also undergone an organizational transformation, dividing its structure into three groups: LDG, AMG, and ACG. These are the recent developments in Waters Corp. and Agilent Technologies Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.